Orthocell Ltd (ASX: OCC) shares are having a strong session on Wednesday.
In morning trade, the ASX healthcare stock is up 7% to $1.09.
Why is this ASX healthcare stock jumping?
Investors have been buying the regenerative medicine company's shares after it announced the first commercial sales of its Remplir product in Hong Kong. Management notes that this marks a key milestone in its Asian growth strategy.
Remplir is a collagen wrap used in nerve repair surgery to improve regeneration of damaged nerves and patient outcomes.
According to the release, these initial sales follow the successful introduction of Remplir in Hong Kong, including its first surgical use and strong reception at the Hong Kong Orthopaedic Association (HKOA) 45th Annual Congress.
The first sales were to MontsMed and provide immediate in-market availability and are expected to support multiple downstream sales as surgeons adopt the technology.
The ASX healthcare stock notes that Hong Kong represents a significant growth opportunity, serving as a strategic entry point into the Guangdong–Hong Kong–Macao Greater Bay Area (GBA). This is a rapidly developing healthcare market of approximately 100 million people.
Strongly positioned
Together with MontsMed, Orthocell is strongly positioned to drive market penetration through leading hospitals and specialist surgeons across the region.
To further accelerate commercial traction, Orthocell's recently appointed Asia Pacific commercial director will be active in market from the first quarter of 2026.
It highlights that working closely with MontsMed, the commercial director will support awareness-building initiatives, surgeon education, and the expansion of Remplir sales across Hong Kong, with broader responsibilities across Australia and Asia.
Commenting on the news, Orthocell's CEO and managing director, Paul Anderson, said:
First Hong Kong sales represent an important commercial milestone for Orthocell and a strong validation of Remplir's clinical value. We are well positioned to support MontsMed in driving adoption across leading hospitals in Hong Kong and the Greater Bay Area. We are executing our commercialisation strategy with discipline, and today's achievement marks another step forward in establishing Remplir as a new standard of care in peripheral nerve repair.
The company also notes that with ~$50 million in cash and no debt, it remains strongly funded and well-positioned to drive rapid product adoption and deliver a step change in revenue in FY 2026.
It also advised that the Remplir rollout in the US$1.6 billion US market continues to build momentum. It revealed that in-country representatives are working closely with distributors to gain hospital approvals, onboard surgeons, and establish active accounts.
